DTcP vaccine is for infants (below 2 years old), addresses the
weaker protection preventing pertussis after primary vaccination.
We are developing a potential China best-in-class DTcP vaccine
for infants. As compared with the co-purified DTaP vaccines,
ourDTcP Infant candidate demonstrates fewer sideeffects and
conveys better and more consistent immunogenicity.
As compared with Pentaxim, which is the only vaccine in
China with a DTcP component, our DTcP Infant candidate demonstrated better immunogenicity in pre-clinical studies. Our DTcP Infant candidate received CTA approval in 2018. We have commenced a phase I clinical trial, which we expect to complete in 2019.
Copyright © ( 2017) CanSino Biologics Inc
For the record: 津ICP备14006666号-2